Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Toxicology ; 125(1): 45-52, 1998 Jan 16.
Artigo em Inglês | MEDLINE | ID: mdl-9585099

RESUMO

The mutagenic potential of carbamazepine (CBZ) therapy has been evaluated both in vivo and in vitro. Analysis of chromosome aberrations (CA), sister chromatid exchanges (SCEs), mitotic and proliferation indices (PRI) were performed. The in vivo study was carried out on 30 patients with idiopathic epilepsy end undergoing treatment with CBZ for different periods starting from 6 months up to 15 years. Plasma CBZ levels were also determined for each patient. The results showed that the total CA and SCEs were significantly increased in CBZ-treated patients. There was no significant correlation between CA and either duration of treatment or the plasma CBZ levels for each patient. The mitotic and proliferation indices were found to be slightly but non-significantly decreased compared to control values. On the other hand, in vitro analysis showed a significant dose-dependent increase in CA and SCEs in human lymphocyte cultures treated with CBZ (4-12 microg/ml). The mitotic and proliferation indices were also found to be decreased but only significantly in case of high doses of CBZ (12 microg/ml). Pretreatment of human lymphocytes with melatonin (0.5 mM) exhibited a significant decrease in the frequencies of CBZ-induced CA and SCEs as compared with non-treated cultures. The depressed mitotic and proliferation indices were also found to be improved in cultures pretreated with melatonin. In conclusion, these observations suggest that CBZ monotherapy may lead to chromosome damaging effects (genotoxic) and the use of melatonin as anti-mutagenic agent for human protection against CBZ-induced chromosome damage should be considered.


Assuntos
Anticonvulsivantes/toxicidade , Carbamazepina/toxicidade , Linfócitos/efeitos dos fármacos , Melatonina/farmacologia , Testes de Mutagenicidade , Adulto , Anticonvulsivantes/antagonistas & inibidores , Anticonvulsivantes/sangue , Carbamazepina/antagonistas & inibidores , Carbamazepina/sangue , Aberrações Cromossômicas , Feminino , Humanos , Linfócitos/ultraestrutura , Masculino , Troca de Cromátide Irmã
2.
J Egypt Soc Parasitol ; 26(2): 497-508, 1996 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8754657

RESUMO

The effects of some parasitic infection (bilharziasis, toxocariasis and trichinosis) on the brain of experimentally infected mice were investigated. Eighty animals were classified into four groups, group I contained five non infected animals as a control group. The other groups each contained twenty-five mice infected with Schistosoma mansoni (group II), Toxocara canis (group III) and Trichinella spiralis (group IV). Each infected group was divided into two subgroups (a,b). Subgroup (a) left untreated and subgroups (b) treated by praziquantel (in group II) and mebendazole (in group III and IV). Histopathological and immunological examination using peroxidase antiperoxidase (PAP) technique and neurotransmitters estimation (nor-epinephrine, dopamine and serotonine) were carried. In the untreated animals, there were mild histopathological changes and mild antigenic deposition in subgroups (IIa and IIIa) and marked changes in subgroup (IVa). There were significant decrease in dopamine in subgroup (IIIa), not improved after treatment (subgroup IIIb) and significant decrease in nor-epinephrine and serotonine in subgroup (IVa) improved after treatment in subgroup (IVb). The neurotransmitters changes may explain the motor, behavioural and emotional changes that occurred with these parasites.


Assuntos
Encéfalo/metabolismo , Mebendazol/uso terapêutico , Neurotransmissores/metabolismo , Doenças Parasitárias/tratamento farmacológico , Doenças Parasitárias/fisiopatologia , Praziquantel/uso terapêutico , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Dopamina/metabolismo , Camundongos , Norepinefrina/metabolismo , Esquistossomose mansoni/tratamento farmacológico , Esquistossomose mansoni/fisiopatologia , Serotonina/metabolismo , Toxocara canis , Toxocaríase/tratamento farmacológico , Toxocaríase/fisiopatologia , Trichinella spiralis , Triquinelose/tratamento farmacológico , Triquinelose/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...